Drugs / rifaximine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02931123 | Nov 2015 → Nov 2017 | — | University of Roma La Sapienza | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02163837 | Mar 2014 → Jul 2015 | hepatic encephalopathy | Centre Hospitalier Universitaire Saint Pierre | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02334163 Comparator | Dec 2014 → Feb 2015 | hepatic encephalopathy | Ain Shams University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rifaximine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02931123 ↗ |
| Route | Oral | “rifaximine, an oral broad spectrum antibiotic” NCT02163837 ↗ |